Welcome to our dedicated page for Veracyte SEC filings (Ticker: VCYT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Veracyte, Inc. (Nasdaq: VCYT) SEC filings, offering a detailed view into the company’s financial reporting, governance decisions, and key disclosures. Veracyte is a global cancer diagnostics and genomic testing company whose filings reflect its activities in developing and commercializing tests such as Decipher Prostate, Afirma GSC, Prosigna, Decipher Bladder, and the Percepta Nasal Swab test, as well as research platforms like Afirma GRID and Decipher GRID.
Investors can review Veracyte’s periodic reports on Forms 10-K and 10-Q for information about revenue composition, testing volumes, cost structure, and risk factors. Current reports on Form 8-K capture specific events, such as the release of quarterly financial results or shareholder votes. For example, recent 8-K filings describe quarterly earnings press releases and the approval of amendments to the company’s equity incentive plan, along with voting outcomes at the annual meeting of stockholders.
These filings also discuss Veracyte’s use of non-GAAP financial measures, including adjusted EBITDA and adjusted EBITDA margin, and explain which items are excluded from these metrics, such as amortization of acquired intangible assets, acquisition-related expenses, stock-based compensation, and certain restructuring costs. This context helps readers understand how management evaluates the company’s performance relative to GAAP results.
On Stock Titan, Veracyte filings are updated in near real time as they are posted to the SEC’s EDGAR system. AI-powered summaries highlight the main points of lengthy documents, helping users quickly identify key topics such as revenue trends, test portfolio updates, equity plan changes, and shareholder voting results. Users can also monitor forms that may relate to insider activity and executive compensation through the company’s proxy and related disclosures, using the AI tools to navigate complex regulatory language more efficiently.
Veracyte Director Evan Jones received a grant of 9,321 restricted stock units (RSUs) on June 18, 2025. Following this transaction, Jones beneficially owns a total of 43,664 shares directly.
Key terms of the RSU grant:
- RSUs vest in full on the first anniversary of the grant date
- Alternative vesting occurs immediately prior to the company's next annual stockholder meeting, if earlier
- Accelerated vesting provision triggers upon a change in control
- Grant price: $0
The Form 4 was filed on June 23, 2025, within the required reporting window. The transaction was executed under transaction code 'A' indicating an acquisition of securities. This equity grant appears to be part of the company's director compensation program.
Veracyte Director Robert S. Epstein received a grant of 9,321 restricted stock units (RSUs) on June 18, 2025. Following this transaction, Epstein's direct ownership increased to 73,919 shares.
Key terms of the RSU award:
- Vesting occurs in full on the first anniversary of the grant date
- Alternative vesting trigger: immediately prior to the company's next annual meeting of stockholders, if earlier
- Accelerated vesting provision in the event of a change in control
- Grant price: $0
The Form 4 was filed on June 23, 2025, within the required reporting window. The transaction was executed under transaction code 'A' indicating an acquisition of securities. This equity grant appears to be part of Veracyte's director compensation program.
Form 4 filing for Veracyte, Inc. (VCYT) discloses that director Eliav Barr received 9,321 restricted stock units (RSUs) on 18-Jun-2025. The grant price is shown as $0 because RSUs are awarded, not purchased. After the award, Barr’s direct ownership rises to 51,189 common shares.
The RSUs vest 100 % on the first anniversary of the grant or immediately before the next annual shareholder meeting, whichever occurs first. Full vesting also accelerates upon a change-in-control event. No derivative transactions were reported, and no sales occurred.
This filing signals routine board compensation rather than an open-market purchase. While it incrementally increases insider alignment with shareholders, the share count is small and has minimal dilution impact for Veracyte’s ~72 million outstanding shares (figure not in filing). Investors typically view RSU awards as neutral to slightly positive, given the absence of cash outlay and the long-term incentive structure.
Veracyte, Inc. (VCYT) – Form 4 Insider Filing
Director Thomas F. Miller reported the award of 9,321 restricted stock units (RSUs) on 18 June 2025. The RSUs were granted at no cost as part of routine director compensation and will vest in full on the first anniversary of the grant date or immediately before the company’s next annual shareholders’ meeting, whichever occurs first. Vesting also accelerates upon a change in control. Following the grant, Miller’s direct beneficial ownership increased to 25,828 common shares. No open-market purchases, sales, or derivative transactions were disclosed. The filing represents a standard equity compensation event and results in only immaterial dilution relative to Veracyte’s total shares outstanding.
Veracyte, Inc. (VCYT) – Form 4 insider transaction
On 18 June 2025, non-employee director David Brent Shafer was granted 9,321 restricted stock units (RSUs) at a cost basis of $0.00. The award increases his direct beneficial ownership to 25,828 common shares.
The RSUs vest in full on the earlier of (i) the first anniversary of the grant date or (ii) immediately prior to the company’s next annual shareholder meeting, with full acceleration upon a change-in-control. No derivative securities were reported.
This filing reflects routine director equity compensation intended to align board and shareholder interests; it does not involve an open-market purchase or sale and therefore has limited immediate market impact.
Veracyte, Inc. (VCYT) filed an 8-K to disclose the voting results of its 17 June 2025 Annual Meeting and related governance actions. Stockholders elected all seven director nominees with support levels ranging from 93.8% to 98.3% of votes cast (excluding broker non-votes). Ernst & Young LLP was ratified as independent auditor for FY-2025 with 99.7% approval.
A key item was a 2.5 million-share increase to the 2023 Equity Incentive Plan. The amendment passed with 72.6% of votes cast (50.6 m For, 19.1 m Against). Assuming full issuance, potential dilution equals roughly 3.4% of the 73.3 million shares outstanding reported in the company’s February 2025 10-K. While the plan expansion strengthens Veracyte’s ability to attract and retain talent in a competitive diagnostics market, it also modestly dilutes existing holders.
Shareholders backed executive compensation in a non-binding “say-on-pay” vote (97.3% approval) and endorsed an annual frequency for future say-on-pay votes (96.2% choosing one-year cadence). The Board has adopted this schedule until at least the 2031 meeting.
Overall, the meeting reinforced management’s governance platform, maintained auditor continuity, and provided additional equity capacity. No immediate financial results or operational updates were included; therefore, market impact is likely limited to perceptions around future dilution and compensation alignment.